* Additional phase 1 data from ECHO-202 reinforce durability
of response in patients with treatment-naive advanced or
metastatic melanoma treated with epacadostat in combination with
keytruda…
The post BRIEF-Incyte Corp provides additional Phase 1 Data from ECHO-202 trial appeared first on NASDAQ.